GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Price-to-Owner-Earnings

Sumitomo Pharma Co (Sumitomo Pharma Co) Price-to-Owner-Earnings : (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Price-to-Owner-Earnings?

As of today (2024-04-26), Sumitomo Pharma Co's share price is $2.70. Sumitomo Pharma Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sumitomo Pharma Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Sumitomo Pharma Co was 506.70. The lowest was 2.56. And the median was 10.06.


DNPUF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.64
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-26), Sumitomo Pharma Co's share price is $2.70. Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.11. Therefore, Sumitomo Pharma Co's PE Ratio for today is At Loss.

As of today (2024-04-26), Sumitomo Pharma Co's share price is $2.70. Sumitomo Pharma Co's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.11. Therefore, Sumitomo Pharma Co's PE Ratio without NRI for today is At Loss.

During the past 13 years, Sumitomo Pharma Co's highest PE Ratio without NRI was 168.07. The lowest was 0.00. And the median was 20.67.


Sumitomo Pharma Co Price-to-Owner-Earnings Historical Data

The historical data trend for Sumitomo Pharma Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Price-to-Owner-Earnings Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.14 7.49 4.37 5.16 7.97

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 7.97 - - -

Competitive Comparison of Sumitomo Pharma Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Price-to-Owner-Earnings falls into.



Sumitomo Pharma Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sumitomo Pharma Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.70/-2.94
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sumitomo Pharma Co  (OTCPK:DNPUF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sumitomo Pharma Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.